Biostatistics Blog

Precision medicine is reshaping the landscape of medtech by tailoring treatments and diagnostics to each patient’s unique clinical profile. As innovative devices and diagnostics enter the market, it becomes critical to understand not only whether they work, but how much, and for whom. Causal inference offers a robust statistical framework for distinguishing true treatment effects from associations, a challenge that is particularly pronounced in observational studies and real-world data settings.Regulatory bodies are increasingly recognising the value of causal inference methods for generating real-world evidence. In the EU, MDR Annex XIV Part B and MDCG guidance 2020-7/2020-8 outline post-market clinical follow-up (PMCF) requirements that often rely on observational data; MDCG 2020-7 names real-world evidence analysis as a PMCF method and requires manufacturers to justify the suitability of the methodology chosen. In the US, the FDA’s December 2025 guidance “Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices” acknowledges the role of rigorous observational study designs in supplementing pivotal trial findings and in supporting expanded indications for use [1]. Both frameworks are in motion: in December 2025 the European Commission published a proposal to revise the MDR and IVDR, reformulating Article 61 and several post-market surveillance provisions, which is currently progressing through the ordinary legislative procedure.This blog post explores how causal inference methods can be applied in the medtech context to enhance evidence gathering in precision medicine.Establishing Causality in Medtech ResearchRandomised controlled trials (RCTs) have long been considered the gold standard for determining causality in terms of treatment efficacy. However, RCTs are not always feasible or ethical, especially in a context where apps or devices may be iteratively improved or used in real-world settings. Observational data from electronic health records (EHRs), wearable sensors, and remote monitoring systems are increasingly important sources of evidence. In such settings, confounding variables can obscure the true effect of an intervention.Causal inference methods, such as propensity score matching (PSM), have been widely adopted to address these challenges. Austin [2] provides an extensive review of propensity score methods, demonstrating how matching patients on observed covariates balances treated and untreated groups. It must be stated plainly that PSM addresses only measured confounders. In EHR and registry data, many of the most important confounders are frequently unrecorded. These might include: frailty, disease severity, and clinician judgement about who is a viable candidate for treatment. No amount of propensity adjustment touches unmeasured confounding at all. Because residual confounding cannot be eliminated, it should be quantified: quantitative bias analysis, such as calculating E-values [3], and negative control outcomes [4] allow researchers to assess how much unmeasured confounding would be required to overturn a finding. Directed Acyclic Graphs (DAGs) provide a complementary framework for stating assumptions about these confounding structures explicitly, before an estimation method is chosen.Instrumental variable (IV) analysis is especially useful when unobserved confounders may bias results. In medtech, natural experiments (such as variations in the adoption rates of a new diagnostic tool across different hospitals) can serve as instruments. Angrist and Pischke [5] discuss how IV methods infer causality in applied econometrics. Provider- and facility-level practice variation is an established instrument family [6]. For an IV to be valid, four core assumptions must hold: independence (the instrument is as-good-as-randomly assigned with respect to unmeasured determinants of the outcome), relevance (the instrument strongly predicts treatment), exclusion (the instrument affects outcomes only through treatment), and monotonicity (if the target is a local average treatment effect). Facility-level instruments are vulnerable on two of these, and the failures are distinct. Adoption tracks hospital size, teaching status and case mix, which are unmeasured determinants of outcome correlated with the instrument, an independence failure. Adopting hospitals may also deliver different co-interventions alongside the device, opening a second pathway to the outcome—an exclusion failure. Both require an explicit argument alongside balance diagnostics [7].Integrating Causal Inference with Machine LearningMachine learning (ML) has further enriched the causal inference toolkit. Traditional statistical models can be combined with ML techniques to handle high-dimensional data for evaluating heterogeneous treatment effects (HTE) across different patient subgroups. Causal forests, which extend the causal tree framework of Athey and Imbens [8] by averaging across many trees, estimate conditional average treatment effects (CATEs) without requiring the moderating covariates to be nominated in advance [9]. (These covariates must still be measured and included in the model.) This suits the question of which patient subgroups derive most benefit from a device intervention, which conventional interaction models can only answer for moderators specified a priori. Because subgroup effect estimation is prone to overfitting and false discovery, causal forests use honest splitting, employing disjoint subsamples for tree-splitting and effect estimation, to support valid inference. Like PSM, these ML methods require unconfoundedness and positivity to yield valid causal estimates. When rigorously applied, HTE analysis can help ensure that treatments are optimally matched to those most likely to benefit.Structural equation modelling (SEM) is also used to map out the causal pathways between device interventions and clinical outcomes. By delineating both direct and indirect effects, SEM offers a structured account of how innovations in medtech may influence patient care. Decomposing direct and indirect effects requires strong assumptions [10]: no unmeasured exposure-outcome confounding, no unmeasured mediator-outcome confounding, no unmeasured exposure-mediator confounding, correct functional form, and no exposure-induced confounding of the mediator-outcome relationship. The last of these is easily violated in device pathways—for instance, where a device alert triggers an intermediate clinical action that both changes management and independently affects the outcome. SEM is therefore best presented as a structured hypothesis about mechanism, with its assumptions stated, rather than as a demonstrated causal cascade.Enhancing Post-Market Surveillance of Medical DevicesCausal inference plays a crucial role in post-market surveillance. Observational studies conducted in post-market settings can suffer from biases that obscure a device’s true performance over time. Techniques such as difference-in-differences (DiD) analysis and targeted maximum likelihood estimation (TMLE) [11] are employed to assess the ongoing impact of the technology. DiD is an identification strategy that differences out time-invariant unobserved confounding under an assumption of parallel trends. TMLE is a doubly-robust estimation approach that combines machine learning with causal inference to reduce bias, though, like PSM, it addresses measured confounders only.For example, DiD is a standard method for evaluating health policy changes [12]. It can be used to evaluate the impact of remote patient monitoring technologies on hospital readmission rates by comparing readmission trends before and after the implementation of monitoring programmes across different health systems. Such analyses can help attribute observed changes to the medtech intervention rather than to broader secular trends, provided the parallel trends assumption is argued and evidenced with pre-period data rather than simply asserted.From Diagnostic Accuracy to Personalised Treatment StrategiesA compelling application of causal inference in precision medicine is its ability to inform personalised treatment strategies. A practical example can be found in the evaluation of AI-driven diagnostic tools. In a study evaluating the CheXNeXt deep learning algorithm for chest radiograph diagnosis, researchers compared the algorithm’s performance against practicing radiologists across 14 pathologies using a dataset from a single institution [13]. The reference standard was the majority vote of three cardiothoracic radiologists. CheXNeXt outperformed radiologists on atelectasis, while radiologists were significantly better on cardiomegaly, emphysema, and hiatal hernia, with no significant differences on the other 10 pathologies.This study reports pathology-level variation in accuracy, not subgroup-level variation. Heterogeneous treatment effects concern variation in the causal effect of an intervention on an outcome across patient subgroups. The bridge from measurement to HTE can be built by specifying the intervention and the outcome: if the algorithm’s output changes clinical management, and management changes patient outcomes, then the causal effect of deploying the algorithm may vary by patient subgroup. This occurs partly through accuracy and partly through how clinicians respond to it. Subgroup-level variation is the relevant analogue, though it was not reported in this study. Defining this intervention and outcome transforms a measurement question into a defensible HTE question: one that shows where along the chain from detection to management to patient outcome the benefit is being realised or lost. That is a different and more actionable finding than knowing where the algorithm’s accuracy is weakest.Challenges and Future Directions of Causal Inference in MedTechWhile the promise of causal inference in precision medicine is immense, challenges remain. The real constraints in these analyses are unmeasured confounding, positivity violations, and measurement error in EHR-derived covariates. A dominant current framework for addressing these constraints is target trial emulation [14]. This approach forces researchers to explicitly specify the eligibility criteria, treatment strategies, and outcomes of a hypothetical trial, thereby organising the observational analysis around a valid causal estimand. This framework specifically addresses endemic device registry issues such as immortal time bias [15] and prevalent user bias.Methodological development continues. Double/debiased machine learning, for instance, allows flexible estimation of nuisance parameters while retaining valid inference for the treatment effect [16]. But the returns to better estimators are limited when identification is the binding constraint. The larger gains in medtech are likely to come from better study design: prospectively planned registries capturing the covariates that actually drive treatment selection, pre-specified target trial protocols, and routine reporting of sensitivity analyses.Causal inference stands as a critical pillar in advancing precision medicine in the medtech arena. By enabling researchers to untangle complex causal relationships from observational data, these methods allow the benefits of innovative devices and diagnostics to be quantified and attributed, with their assumptions stated and their limitations known. By embracing causal inference alongside rigorous target trial emulation, medtech companies can accelerate the development of truly personalised solutions that improve clinical outcomes and redefine patient care.References[1] U.S. Food and Drug Administration. (2025). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Guidance for Industry and Food and Drug Administration Staff, December 2025. Docket FDA-2023-D-4395.[2] Austin, P.C. (2011). An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behavioral Research, 46(3), 399–424.[3] VanderWeele, T.J., & Ding, P. (2017). Sensitivity Analysis in Observational Research: Introducing the E-Value. Annals of Internal Medicine, 167(4), 268-274.[4] Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010). Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. Epidemiology, 21(3), 383-388.[5] Angrist, J.D., & Pischke, J.S. (2009). Mostly Harmless Econometrics: An Empiricist’s Companion. Princeton University Press.[6] Brookhart, M.A., Wang, P., Solomon, D.H., & Schneeweiss, S. (2006). Evaluating Short-term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable. Epidemiology, 17(3), 268-275.[7] Brookhart, M.A., & Schneeweiss, S. (2007). Preference-based Instrumental Variable Methods for the Estimation of Treatment Effects. International Journal of Biostatistics, 3(1).[8] Athey, S., & Imbens, G. (2016). Recursive Partitioning for Heterogeneous Causal Effects. Proceedings of the National Academy of Sciences, 113(27), 7353–7360.[9] Wager, S., & Athey, S. (2018). Estimation and Inference of Heterogeneous Treatment Effects Using Random Forests. Journal of the American Statistical Association, 113(523), 1228–1242.[10] VanderWeele, T.J. (2015). Explanation in Causal Inference: Methods for Mediation and Interaction. Oxford University Press.[11] van der Laan, M.J., & Rubin, D. (2006). Targeted Maximum Likelihood Learning. The International Journal of Biostatistics, 2(1), Article 11.[12] Dimick, J.B., & Ryan, A.M. (2014). Methods for Evaluating Changes in Health Care Policy: The Difference-in-Differences Approach. JAMA, 312(22), 2401–2402.[13] Rajpurkar, P., Irvin, J., Ball, R.L., et al. (2018). Deep Learning for Chest Radiograph Diagnosis: A Retrospective Comparison of the CheXNeXt Algorithm to Practicing Radiologists. PLoS Medicine, 15(11), e1002686.[14] Hernán, M.A., & Robins, J.M. (2016). Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American Journal of Epidemiology, 183(8), 758-764.[15] Suissa, S. (2008). Immortal Time Bias in Pharmacoepidemiology. American Journal of Epidemiology, 167(4), 492-499.[16] Chernozhukov, V., Chetverikov, D., Demirer, M., et al. (2018). Double/debiased machine learning for treatment and structural parameters. The Econometrics Journal, 21(1), C1-C68.

Precision medicine is transforming healthcare by allowing treatments and diagnostics to be tailored to the unique genetic, molecular, and clinical profiles of individual patients. As research and clinical evaluation evolves, sophisticated analytics have become essential for integrating complex datasets, optimising study designs, and supporting informed decision-making. This article will explore 3 core quantitative approaches core to supporting the development of precision treatment solutions in Medtech.1. Bayesian Adaptive Designs and Master ProtocolsTraditional study designs often fall short of accommodating emerging data and shifting patient profiles. Bayesian adaptive designs offer a solution by enabling the regular updating of initial assumptions as data accumulates. By expressing early hypotheses as prior distributions and then refining them into posterior distributions with incoming trial data, a dynamic assessment of treatment or device performance can be achieved. This real-time updating can enhance the precision of efficacy and safety estimates and supports timely decisions regarding the continuation, modification, or termination of a study. When combined with master protocols, which enable the simultaneous evaluation of multiple interventions through shared control groups and adaptive randomisation, this approach optimises resource use and reduces sample sizes. These methodologies have been well established in pharmaceutical trials, particularly in oncology. Their adaptation to medtech is proving increasingly valuable as the field confronts challenges such as device iteration, real-time data collection, and varied endpoint definitions. While the regulatory framework and trial designs for devices often differ from those in pharma, there is increasing interest in applying these flexible, data-driven approaches.Key elements of Bayesian Adaptive designs include:Prior Distributions and Posterior UpdatingInitial beliefs about treatment or device performance are expressed as prior distributions. As the trial progresses, incoming data are used to update these priors into posterior distributions, providing a dynamic reflection of effectiveness.Predictive Probabilities and Decision RulesBy calculating the likelihood of future outcomes, predictive probabilities inform whether to continue, modify, or halt a trial. This is particularly useful in managing heterogeneous patient populations typical of precision medicine contexts.Decision-Theoretic ApproachesIncorporating loss functions and cost-benefit analyses allows for ethically and economically optimised trial adaptations, ensuring patient safety while maximising resource efficiency.Master Protocols for Efficient Resource UseMaster protocols offer a unified framework for evaluating multiple interventions or device settings concurrently. Their benefits include:Shared Control GroupsUtilising a common control arm across study arms reduces overall sample sizes while maintaining statistical power – an advantage when patient recruitment is challenging.Adaptive RandomisationAlgorithms adjust randomisation ratios in favour of treatments or device settings showing early promise. This increases the ethical profile of a trial by reducing exposure to less effective options and accelerates the evaluation process.Integrated Platform TrialsThese protocols enable the simultaneous assessment of multiple hypotheses or functionalities, streamlining regulatory submissions and expediting market launch.2. Multi‐Omics Insights Through BioinformaticsThe true potential of precision medicine lies in its ability to harness diverse biological data to form a complete picture of patient health. Integrating data from genomics, proteomics, metabolomics, and transcriptomics, for example, enables biomarker discovery, leading to detailed patient profiles that inform targeted interventions. Advanced statistical techniques, such as multivariate and clustering analyses, help process these complex datasets, identifying patterns and segmenting patient populations into meaningful subgroups. When combined with traditional clinical endpoints using survival models like Cox proportional hazards and Kaplan-Meier estimates, multi‐omics insights significantly enhance the precision of outcome predictions.Key Advantages of Multi‐Omics IntegrationHolistic Patient ProfilingBy merging data from multiple biological sources, organisations can uncover novel biomarkers and generate comprehensive patient profiles, contributing to the development of more targeted and effective diagnostic tools and therapies.Improved Patient StratificationDimensionality reduction techniques such as principal component analysis (PCA) and canonical correlation analysis (CCA) simplify high-dimensional omics data, while clustering methods like hierarchical clustering and Gaussian mixture models categorise patients into distinct subgroups. This stratification enables precision in selecting the most suitable interventions for different patient groups.Enhanced Predictive PowerMulti‐omics integration, when combined with clinical endpoints, can improve long-term outcome predictions. Using models like Cox proportional hazards and Kaplan-Meier estimates, survival probabilities and disease progression can be assessed to improve the reliability of clinical decision-making.Comprehensive Data Integration for Personalised InsightsPrecision medicine often relies on the integration of multi‐omics data with traditional clinical measures to refine patient stratification and improve diagnostic accuracy. Medtech devices can be calibrated to detect clinically significant biomarker variations, enhancing both sensitivity and specificity of measurements. By leveraging bioinformatics-driven statistical methods, these insights become actionable and support the development of highly personalised therapeutic and diagnostic solutions.3. Machine Learning for Targeted InsightsMachine learning has emerged as a transformative tool capable of deciphering complex, high-dimensional data with remarkable precision. Techniques such as LASSO regression, random forests, and support vector machines enable the isolation of the most predictive variables from vast datasets, reducing noise and minimising overfitting. Validation methods, including k-fold cross-validation and bootstrapping, evaluate the degree to which models are both accurate and generalisable, which is critical when clinical decisions depend on their outputs. Interpretability tools like SHAP values help stakeholders understand the factors driving model predictions, while continuous learning frameworks allow models to evolve as new data emerges. This adaptability is exemplified in practical applications. For medtech companies, machine learning bridges the gap between raw data and actionable insights. Consider a wearable diagnostic device: ML algorithms can continuously analyse sensor data to detect critical physiological patterns, adapting in real time to deliver personalised feedback and enhance device performance.Machine learning (ML) complements traditional statistical methods by managing large, complex datasets and uncovering non‐linear relationships that might otherwise remain hidden. In precision medicine, ML applications include:Feature Selection and Predictive ModellingAlgorithms such as LASSO regression (which inherently performs feature selection), random forests (which provide feature importance metrics), and support vector machines (SVMs) identify the most predictive features from vast datasets. This process minimises overfitting and enhances model interpretability, critical when tailoring interventions or device functions.Robust Model ValidationTechniques like k‐fold cross‐validation and bootstrapping help ensure that ML models are robust and generalisable. Such rigour is essential for clinical applications where predictive accuracy translates directly into patient outcomes.Model Interpretability and Continuous LearningTools like SHAP (SHapley Additive exPlanations) values help stakeholders understand model decisions, while continuous learning frameworks enable models to evolve as new patient data become available, ensuring that devices and treatments remain optimised over time.A Practical ExampleConsider a wearable cardiovascular diagnostic device undergoing clinical evaluation. Adaptive statistical models continuously update trial parameters based on real-time data so that decision-making is both responsive and informed. Multi-omics analyses stratify patients by genetic markers associated with cardiovascular risk to refine patient selection and enhancing the precision of outcome predictions. Meanwhile, machine learning algorithms process sensor data in real time to detect critical patterns, enabling the device to adapt its performance to the unique physiological profiles of its users.The trial employs:Bayesian adaptive designs to update trial parameters based on real-time data, enhancing decision-making.Multi‐omics analysis to stratify patients by genetic markers linked to cardiovascular risk, refining patient selection.Machine learning algorithms that identify key predictive features from sensor data, continuously adapting device performance.This holistic strategy improves the precision of the trial and optimises the final product to meet specific patient needs.4. Bonus Method: Causal InferenceWhile correlations in data provide valuable insights, understanding causation is key to effective precision medicine. Causal inference methods help differentiate true treatment effects from spurious associations by adjusting for confounding factors, a critical step when working with observational data or real-world evidence. Techniques such as propensity score matching, instrumental variable analysis, and causal forests enable researchers to isolate the impact of specific interventions on patient outcomes. Integrating causal inference into the analytics workflow reinforces the validity of conventional statistical methods and machine learning predictions. It also supports more reliable patient stratification and treatment optimisation. This approach increases the probability that the decisions made during R&D and clinical trials are grounded in true cause-and-effect relationships.To read our full blogpost on the applications of causal inference in precision medicine R&D, see here.Advanced statistics and bioinformatics is transforming the landscape of precision medicine by empowering organisations to make faster, more informed decisions throughout the R&D and clinical trials process. Adaptive clinical study design for real-time adjustments in study parameters improves the chances that a study remains responsive and efficient in assessing clinical endpoints. Multi-omics integration provides insights into patient biology and allows for precise stratification and targeted intervention. Complementing these approaches, advanced machine learning can be used to uncover hidden patterns in complex datasets, further enhancing predictive accuracy and operational efficiency. Although each method operates independently, together they represent a powerful toolkit for accelerating innovation and delivering patient-centred healthcare solutions with greater precision.If you’d like to have an in-depth discussion about how our advanced analytics methods could play a valuable role in your device, app or diagnostic development, do get in touch. We would be more than happy to assess your project and answer any questions.

In clinical trials, the Case Report Form (CRF) is more than a tool for collecting data, it’s the backbone of the study. From capturing critical safety outcomes to evaluating device performance, a well-designed CRF ensures that the study’s goals are met efficiently and reliably.Achieving this balance requires input from two key roles: the data manager and the biostatistician. While their contributions may overlap in some areas, these roles serve distinct and complementary purposes. Understanding how these professionals work together can help medtech sponsors avoid common pitfalls in CRF design and maximise the success of their trials.The Data Manager’s Role in CRF DesignData managers are experts in the operational and technical aspects of CRF design. Their role is to ensure that data collection is standardised, consistent, and compliant with relevant guidelines.Key responsibilities of a data manager include:Formatting CRFs: Ensuring fields are user-friendly and compatible with electronic data capture (EDC) systems.Regulatory Compliance: Aligning CRFs with industry standards such as CDASH (Clinical Data Acquisition Standards Harmonisation).Site Usability: Designing forms that facilitate accurate and consistent data entry across multiple trial sites.For instance, a data manager might ensure that dropdown menus in the CRF prevent free-text responses, reducing the risk of inconsistencies. Their focus is on the practical and technical aspects of data collection.The Biostatistician’s Role in CRF DesignBiostatisticians, on the other hand, approach CRF design from an analytical perspective. Their focus is on ensuring that the data collected aligns with the study’s endpoints and supports meaningful statistical analysis.Key responsibilities of a biostatistician include:Aligning Data with Study Objectives: Defining the variables that need to be captured to evaluate the endpoints outlined in the Statistical Analysis Plan (SAP).Variable Definition: Ensuring that collected data supports statistical methods, such as properly coding categorical variables (e.g., mild/moderate/severe).Derived Metrics: Identifying composite or derived variables that must be pre-defined in the CRF to support downstream analysis.For example, in a post-market study evaluating a vascular device, the biostatistician would ensure that the CRF captures restenosis rates in a format that allows calculation of primary patency – a key endpoint. Their input ensures that no critical data points are overlooked.Why Both Roles Are Essential to MedTech TrialsAlthough data managers and biostatisticians work towards the same goal, collecting high-quality data, their approaches and expertise are fundamentally different. Collaboration between these roles is essential for creating CRFs that are both operationally feasible and analytically robust.1. Preventing Data GapsWithout biostatistician oversight, CRFs may fail to capture key variables required for endpoint evaluation. For example:In a stent study, a missing field for recording restenosis or target vessel occlusion could render the primary endpoint unanalysable.Failure to specify timepoints for data collection (e.g., 12-month vs. 60-month follow-up) may result in incomplete datasets for secondary analyses.2. Ensuring Data CompatibilityWhile data managers ensure that CRFs meet technical and regulatory standards, biostatisticians ensure the data is analysable. Misalignment in variable formats can lead to delays or errors during analysis. For instance:Categorical variables (e.g., adverse event severity) coded as free text at some sites and numeric values at others can complicate statistical programming.3. Regulatory-Ready AnalysisIn medtech trials, regulatory submissions rely heavily on robust statistical reporting. Biostatisticians ensure that CRFs are designed to collect all data necessary for generating high-quality, compliant analyses. For example:Derived metrics like cumulative incidence rates must be pre-defined in the CRF to avoid regulatory scrutiny over post-hoc adjustments.Misconceptions About CRF Design in MedTechA common misconception in medtech trials is that data managers can fully handle CRF design. While data managers are essential for operationalising CRFs, their expertise does not extend to defining the analytical framework needed to support endpoints and hypotheses.The Risks of Excluding Biostatistician InputWhen biostatisticians are excluded from CRF design:Key Variables May Be Missing: Critical fields for evaluating endpoints may be omitted.Data May Be Misaligned: Improperly coded variables can lead to delays during analysis or errors in reporting.Regulatory Challenges May Arise: Incomplete or improperly formatted data can result in regulatory delays or rejection.By including biostatisticians early in the CRF design process, sponsors can avoid these risks and ensure their study remains on track.Real-World Example: The Power of CollaborationConsider a post-market surveillance study for a diagnostic device. The sponsor relies on CRFs to collect data on device performance across real-world clinical settings. Initially, the data manager designed the CRFs to focus on ease of use at the sites. However, the biostatistician identified a critical oversight: the CRFs did not include fields to track device calibration data, a key variable for assessing long-term performance trends. By collaborating, the data manager and biostatistician ensured the CRFs met both operational and analytical requirements, setting the stage for a successful regulatory submission.Practical Steps for MedTech SponsorsTo ensure robust CRF design in your medtech trial, consider these steps:Involve Biostatisticians Early: Engage your biostatistician during the CRF design phase to define variables and ensure alignment with study endpoints.Foster Collaboration: Encourage close communication between data managers and biostatisticians to balance operational efficiency with analytical rigor.Prioritise Regulatory Readiness: Design CRFs with regulatory requirements in mind to avoid costly delays during submission.Final ThoughtsIn medtech clinical trials, the success of your study depends on more than just collecting data – it depends on collecting the right data in the right way. Data managers and biostatisticians each bring unique expertise to CRF design, and their collaboration ensures that your trial is set up for operational efficiency, analytical validity, and regulatory success.By recognising the complementary roles of these professionals, medtech sponsors can avoid common pitfalls and ensure their studies deliver meaningful, actionable results. If you’re planning a clinical trial and want to learn more about how to optimise CRF design, our team at Anatomise Biostats is here to help.

In the medtech industry, a growing misconception equates proficiency in statistical software with competence in clinical trial design. As data pipelines become more automated, statistical analysis is increasingly delegated to professionals from adjacent fields, such as biomedical engineers, bioinformaticians, or data scientists. While these disciplines possess strong computational skills, they often lack the in-depth biostatistical training required to safeguard a clinical trial. The result is a fundamental misalignment between the complexity of the data and the statistical rigor required to interpret it.Clinical trials rarely falter due to a lack of software capability; they fail due to flawed methodological assumptions. A coursework Master’s in Biostatistics provides an indispensable foundation because it trains the mind to evaluate, not just calculate. It builds a nuanced structural understanding of probability theory and hypothesis testing, equipping the biostatistician to identify when standard methods are insufficient. Without this grounding, analysts tend to force messy, real-world clinical data into rigid, textbook templates, often oblivious to the biases being introduced. Ideally, a doctoral thesis in biostatistics should not be a replacement for this broader foundation, but instead should build upon it – if indeed the goal is to function as a biostatistician in industry.This distinction becomes critical when confronting the nuances of study design. Calculating statistical power is rarely a plug-and-play formula; it requires navigating the interplay of effect sizes, variability, and dropout rates, often necessitating simulation to ensure a study is neither underpowered nor wastefully oversized. Hypothesis testing is frequently reduced to the pursuit of p-values, ignoring the complexities of managing false-positive rates across multiple subgroups. Whether integrating prior information via Bayesian modelling without skewing current data, or isolating true treatment effects from confounding variables using propensity scores, these tasks require nuanced decisions that algorithms alone simply cannot make.This methodological gap is particularly evident in complex trial designs, such as evaluating a cardiac monitoring device across a heterogeneous patient population. An analyst without sufficient biostatistical training might default to standard proportional hazards models, assuming the device’s impact is uniform across all demographics and time points. While computationally straightforward, this approach is methodologically blind. It obscures critical variations in efficacy, potentially leading to misguided regulatory conclusions.A post-graduate biostatistician is more likely to approach this complexity as an iterative investigation. Recognising that a one-size-fits-all model fails to capture the reality of clinical data, advanced methodologies are evaluated and tailored. Hierarchical models might be applied to account for site-specific variations, or time-varying covariate models utilised to reflect fluctuating patient health over a study’s duration. Thorough diagnostics are conducted, applying advanced stratification to isolate the device’s effect on specific comorbidities, like diabetes, ensuring the treatment effect is not conflated with baseline health differences. Assumptions are continually tested against unmeasured confounders through exhaustive sensitivity analyses.In clinical R&D, data does not speak for itself; it is interpreted. When the interpretation of clinical evidence is delegated to those without formal post-graduate biostatistical expertise, regulatory submissions and clinical guidelines risk being built on unstable foundations. Biostatistical training is not a bureaucratic hurdle; it is the architecture of clinical truth. Ensuring trials are guided by this expertise is the only way to guarantee that a technology is validated accurately, safely, and for the precise patient populations who stand to benefit.

The integrity of a clinical investigation relies entirely on the precision of its data. As trial designs grow more complex, the scope of biometrics expands accordingly. Biometrics spans biostatistics, statistical programming, and data management. Medtech sponsors often build internal data teams, sometimes assuming that general data science or AI expertise translates to sound regulatory biostatistics. Clinical investigations, however, require a highly specific regulatory and statistical framework.Building a dedicated in-house biometrics function demands substantial capital and specialised infrastructure. Outsourcing offers a strategic alternative, providing access to tailored expertise and ensuring alignment with global regulatory standards.1. Methodological Rigour Clinical trials require a distinct blend of disciplines, from adaptive trial design to regulatory compliance. While internal data scientists possess strong computational skills, they may lack formal training in the probability theory and hypothesis testing required for regulatory submissions. Outsourcing provides immediate access to a cross-functional team of specialists. Every aspect of the study, from Statistical Analysis Plan (SAP) development to database lock, is handled by experts focused solely on statistical integrity, ensuring optimal methodologies are applied without internal bias.2. Operational Scalability The resource demands of a clinical trial naturally fluctuate. A study may require intensive statistical modelling during the design phase, followed by a surge in programming capacity during database lock. Internal teams frequently struggle with these peaks, leading to operational bottlenecks. An outsourced biometrics team provides inherent elasticity, deploying additional statistical programmers precisely when needed to ensure continuous progress without carrying idle resources during quieter phases.3. Quality Assurance In small internal teams, time pressures can occasionally compromise quality control. Without sufficient personnel, independent verification becomes difficult. Outsourced biometrics providers build redundancy into their standard operating procedures, employing multi-layered standardised review processes such as independent double-programming. This ensures the methodology, code, data and reporting undergoes several levels of scrutiny, supporting the overall reliability of the analysis.4. Regulatory Alignment and Infrastructure Sponsors must adhere to stringent standards from the FDA, MHRA, and EU Competent Authorities under the MDR, alongside ICH E6(R3) Good Clinical Practice. Maintaining the validated servers, 21 CFR Part 11 compliant systems, and cybersecurity measures to support this represents a significant ongoing expense. Experienced partners operate within pre-validated, secure infrastructures designed specifically for clinical data. They are well-versed in ALCOA+ principles and standardised data structures like CDISC, ensuring submissions meet global regulatory expectations from the outset.5. Economic Efficiency Building an internal biometrics team is capital-intensive. Beyond salaries, sponsors must fund recruitment, continuous training, software licences (e.g., SAS, nQuery), and administrative overhead. Outsourcing converts these operating expenditures into variable operational costs, allowing sponsors to pay only for the expertise and infrastructure required for the project’s duration.SummaryClinical investigations are complex, and the statistical integrity of the data is paramount. While an in-house team offers a sense of control, it often introduces hidden costs and operational challenges. Outsourcing biometrics ensures that the study design and data analysis is managed with precision, scalability, and strict regulatory compliance. This allows sponsors to focus on their core competency: developing breakthrough medical technologies.If you are preparing for your next clinical investigation, a robust statistical framework is essential. Contact Anatomise Biostats to discuss how our specialised biometrics team can support your trial design, data management, and regulatory submission strategy.

The ethical and accurate handling of data is paramount in the domain of clinical research. As the demand for data-driven clinical insights continues to grow, researchers face challenges in balancing the need for accuracy with the availability of data and the imperative to protect sensitive information. In situations where not enough quality real patient data is available, synthetic data can be the most reliable data source from which to derive predictive insights. Synthetic data can be more cost-effective and time-efficient in many cases than acquiring the equivalent real data.Synthetic data must be differentiated from fake data. In recent years there has been much controversy concerning fake data detected in published journal articles which have previously passed peer review, particularly in an academic context. As one study is generally built upon assumptions formed by the results of another, this preponderance of fake data has really had a catastrophic impact on our ability to trust any published scientific research, regardless of whether the study at hand also contains fake data. It has become clear that the implementation of increased quality control standards for all published research needs to be prioritised.While synthetic data is not without pitfalls, the key difference between synthetic and fake data lies in its purpose and authenticity. Synthetic data is legitimately designed to emulate real-world data for specific use cases, maintaining statistical properties without revealing actual (individual) information. On the other hand, fake data is typically fabricated or, at best, the result of improper handling. It may or may not adhere to any real-world patterns or statistics.In clinical research, the use of real patient data is fraught with privacy concerns and other ethical considerations. Accurate and consistent patient data can also be hard to come by for other reasons such as heterogeneous recording methods or insufficient disease populations. Synthetic data is emerging as a powerful solution to navigate these limitations. While accurate synthetic data is not a trivial thing to generate, researchers can harness advanced algorithms and models built by expert data scientists to generate synthetic datasets that faithfully mimic the statistical properties and patterns of real-world patient and other data. This allows researchers to simulate and predict relevant clinical outcomes in situations where real data is not readily available, and do so without compromising individual patient privacy.A large proportion of machine learning models in an AI context are currently being trained on synthetic rather than real data. This is largely because using generative models to create synthetic data tends to be much faster and cheaper than collecting real-world-data. Real-world data can at times lack sufficient diversity to make insights and predictions truly generalisable.Both the irresponsible use of synthetic data and the generation and application of fake data in academic, industry and clinical research settings can have severe consequences. Whether stemming from dishonesty or incompetence, the misuse of fake data or inaccurate synthetic data poses a threat to the integrity of scientific inquiry.This following sections define and delineate between synthetic and fake data as well as summarise the key applications of synthetic data in clinical research as compared to the potential pitfalls associated with the unethical use of fake data.Synthetic Data:Synthetic data refers to artificially generated data that mimics the statistical properties and patterns of real-world data. It is created using various algorithms, models, or simulations to resemble authentic patient data as closely as possible. It may do so without containing any real-world identifying information about individual patients comprising the original patient sample from which it was derived.Synthetic data can be used in situations where privacy, security, or confidentiality concerns make it challenging to access or use real patient data. It can also be used in cases where an insufficient volume of quality patient data is available or where existing data is too heterogeneous to draw accurate inferences, such as is typically the case with rare diseases. It can potentially be employed in product testing to create realistic scenarios without subjecting real patients to unnecessary risk.3 key use cases for synthetic data in clinical research1. Privacy Preservation:– Synthetic data allows researchers to conduct analyses and develop statistical models without exposing sensitive patient information. This is particularly crucial in the healthcare and clinical research sectors, where maintaining patient confidentiality is a legal and ethical imperative.2. Robust Testing Environments:– Clinical trials and other experiments related to product testing or behavioural interventions often necessitate testing in various scenarios. Synthetic data provides a versatile and secure testing ground, enabling researchers to validate algorithms and methodologies without putting real patients at risk.3. Data Augmentation for Limited Datasets:– In situations where obtaining a large and diverse dataset is challenging, synthetic data serves as a valuable tool for augmenting existing datasets. This aids in the development of more robust models and generalisable findings. A data set can be made up of varying proportions of synthetic versus real-world data. For example, a real world data set may be fairly large but lack diversity on the one hand, or small and overly heterogeneous on the other. The methods of generating synthetic data to augment these respective data sets would differ in each case.Fake Data:Fake data typically refers to data that is intentionally fabricated or inaccurate due to improper data handling techniques. In situations of misuse it is usually combined with real study data to give misleading results.Fake data can be used ethically for various purposes, such as placeholder values in a database during development, creating fictional scenarios for training or educational purposes, or generating data for scenarios where realism is not crucial. Unfortunately in the majority of notable academic and clinical cases it has been used with the deliberate intention to mislead by doctoring study results and thus poses a serious threat to the scientific community and the general public..There are three key concerns with fake data.1. Academic Dishonesty:– Some researchers may be tempted to fabricate data to support preconceived conclusions, meet publication deadlines or attain competitive research grants. After many high profile cases in recent years it has become apparent that this is a pervasive issue across academic and clinical research. This form of academic dishonesty undermines the foundation of scholarly pursuits and erodes the trust placed in research findings.2. Mishaps and Ineptitude:– Inexperienced researchers may inadvertently create fake data, whether due to poor data collection practices, computational errors, or other mishaps. This unintentional misuse can lead to inaccurate results, potentially rendering an entire body of research unreliable if it remains undetected.3. Erosion of Trust and Reproducibility:– The use of fake data contributes to the reproducibility crisis in scientific research. One study found that 70% of researchers were unable to reproduce studies of interest due to insufficient reporting of data and methods. When results cannot be independently verified, trust in the scientific process diminishes, hindering the advancement of knowledge. The addition of fake data into this scenario makes replication and thus verification of study results all the more challenging.In an evolving clinical research landscape, the responsible and ethical use of data is paramount. Synthetic data stands out as a valuable tool in protecting privacy, advancing research, and addressing the challenges posed by sensitive information – assuming it is generated as accurately and responsibly as possible. On the other hand, the misuse of fake data undermines the integrity of scientific research, eroding trust and impeding the progress of knowledge and it’s real-world applications. It is important to stay vigilant against bias in data and employ stringent quality control in all data contexts of data handling.

Clinical-translational studies represent the critical inflection point where a diagnostic technology transitions from a laboratory assay to a validated clinical asset. Understanding the distinction between translational research and formal clinical investigations, and how they sequence together, is essential for designing an efficient regulatory and statistical strategy.Navigating the Diagnostic Device LandscapeBefore examining the translational phase, it is vital to distinguish between the two primary categories of diagnostic devices, as they are governed by different regulatory frameworks:In Vitro Diagnostics (IVDs): Devices that examine specimens derived from the human body (e.g., molecular assays, lateral flow tests). These are regulated in the EU under the IVDR (2017/746) and internationally by ISO 20916 for clinical performance studies.In Vivo Diagnostic Devices: Devices used to scan, image, or monitor the living body (e.g., AI-imaging software, continuous glucose monitors, ECG devices). In the EU, these are regulated under the Medical Device Regulation (MDR 2017/745) and internationally by ISO 14155 for clinical investigations.Despite these regulatory differences, both categories share a fundamental developmental pipeline: moving from analytical/technical validity, to clinical validity, and finally to clinical utility.Translational Studies vs. Clinical InvestigationsA translational study does not “turn into” a clinical investigation. Rather, they are sequential, distinct phases.Clinical-Translational Studies (Clinical Validity): These studies focus on proving that the device or assay can accurately detect or predict a specific clinical condition in the intended-use population. For IVDs, this might involve retrospective testing of biobanked specimens. For in vivo devices (like AI imaging), this might involve a retrospective analysis of previously acquired patient scans. These studies establish the foundational metrics of diagnostic accuracy but do not dictate real-time patient management.Clinical Investigations (Clinical Utility): These are formal, prospective trials where the device is used in real-time to guide actual patient care. The goal is to prove that using the test changes clinical decisions and meaningfully improves health outcomes compared to the standard of care.The clinical validity data generated in the translational phase acts as the statistical and scientific justification for initiating a formal clinical investigation. If the translational study fails to demonstrate sufficient accuracy, a prospective investigation is unjustified.Core Components of Clinical-Translational Studies1. Establishing the Statistical Foundation for Investigation While sensitivity and specificity are the foundational metrics of clinical validity, they are prevalence-independent measures. Translational studies employ comprehensive biostatistical analyses, including Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) calculations, to evaluate the trade-off between sensitivity and specificity across all possible cut-off points.Crucially, this analysis allows a sponsor to “lock” the diagnostic threshold (e.g., a specific biomarker concentration for an IVD, or a pixel-density threshold for an AI imaging device) before entering a prospective clinical investigation. Changing a threshold mid-trial introduces severe regulatory bias. Translational studies also calculate Positive Predictive Values (PPV) and Negative Predictive Values (NPV) to reflect the test’s performance in the context of actual disease prevalence, ensuring the subsequent investigation is powered correctly.2. Mitigating Spectrum Bias and Ensuring Generalisability A frequent pitfall in early translational research is spectrum bias, which occurs when the study population does not accurately reflect the intended-use population. Testing a device exclusively on severe cases and healthy controls will artificially inflate its apparent accuracy.Translational studies must be designed to include a broad spectrum of patients encompassing varying demographics, comorbidities, and disease severities. Biostatisticians employ stratified analyses and multivariable regression models to identify potential variations in test performance across subgroups. This ensures that when the novel diagnostic finally enters a clinical investigation, the inclusion/exclusion criteria are statistically sound and generalisable to real-world settings.3. Handling Imperfect Reference Standards A major statistical challenge in translational diagnostics is the lack of a perfect “gold standard.” If the existing standard of care is flawed, comparing a new device to it will produce biased accuracy estimates.Translational studies often utilise advanced statistical modelling to handle this, using methods such as composite reference standards (CRS) or latent class models. Resolving these reference standard issues during the translational phase is critical; if left unresolved, they can invalidate the endpoints of a future clinical investigation.4. Preparing for Real-World Evidence (RWE) and Longitudinal Monitoring While translational studies are not full clinical investigations, they must be designed with future regulatory expectations in mind. Under both the EU IVDR (Annex XIII Part B) and MDR (Annex XIV Part B), Post-Market Clinical Follow-up (PMCF) or Post-Market Performance Follow-up (PMPF) are regulatory requirements.Early integration of RWE methodologies during the translational phase involves using advanced statistical techniques to control for confounding in routine clinical data. This helps sponsors anticipate algorithmic drift (particularly in AI/ML diagnostics). For diagnostics intended for monitoring disease progression, longitudinal translational designs using mixed-effects models are necessary to prove the device can track clinical changes over time before a costly interventional investigation begins.The Biostatistical ImperativeThe complexity of modern diagnostic devices demands biostatistical involvement from the outset of the translational phase. Biostatisticians are essential for calculating precise sample sizes (e.g., using Buderer’s formula for sensitivity/specificity precision based on desired confidence interval widths), designing retrospective or cross-sectional cohorts that minimise bias, and resolving reference standard ambiguities.By establishing unassailable clinical validity through robust translational studies, sponsors ensure they have the statistical evidence required to justify and design a successful clinical investigation – ultimately accelerating the path to market and patient access.For more information on our services for clinical-translational studies see here.If you are designing a clinical-translational study to establish the clinical validity of your diagnostic device or IVD, the statistical framework must be robust from day one. Contact Anatomise Biostats to discuss how our team can support your study design, sample size calculations, and regulatory submission strategy.References & Regulatory FrameworksEuropean Union. (2017). Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices (IVDR). (Specifically Article 57 and 58 for Clinical Performance Studies, and Annex XIII Part B for post-market performance follow-up).European Union. (2017). Regulation (EU) 2017/745 on Medical Devices (MDR). (Applies to in vivo diagnostic devices, imaging equipment, and AI software; see Chapter VI for Clinical Investigations).International Organization for Standardization (ISO). (2019). ISO 20916:2019 – In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects — Good study practice.International Organization for Standardization (ISO). (2021). ISO 14155:2021 – Clinical investigation of medical devices for human subjects — Good clinical practice.U.S. Food and Drug Administration (FDA). (2007). Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests. (Covers the statistical principles of ROC curves, spectrum bias, and PPV/NPV reporting).Buderer, N. M. (1996). Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Academic Emergency Medicine, 3(9), 895-900. (The foundational formula for diagnostic sample size calculation based on precision).Rutjes, A. W., Reitsma, J. B., Coomarasamy, A., Khan, K. S., & Bossuyt, P. M. (2007). Evaluation of diagnostic tests when there is no gold standard: A review of methods. Health Technology Assessment, 11(50). (Details the use of Composite Reference Standards and latent class models).

In the highly regulated medical device sector, compliance cannot be retrofitted onto a finished product. A proactive, “compliance-by-design” approach that integrates regulatory and biostatistical considerations from concept through post-market is essential for market approval and patient safety.Below is a concise framework for embedding regulatory rigour into your R&D and clinical trial processes.Phase 1: R&D and Quality FrameworkRegulatory Strategy & Gap Analysis: Engage regulatory experts at concept stage to define the device classification and regulatory pathway (e.g., FDA 510(k)/De Novo, EU MDR/IVDR). Conduct early gap analyses against target regulations to prevent costly late-stage redesigns.Implement a Robust QMS: Establish a Quality Management System aligned with ISO 13485:2016 and the FDA’s QMSR (21 CFR Part 820) early. This ensures design controls, document traceability, and process validation are built into the R&D lifecycle.Design Controls & Traceability: Maintain a continuous traceability matrix linking User Needs, Design Inputs, Design Outputs, and Verification/Validation (V&V) activities.Integrated Risk Management: Conduct ongoing risk management in line with ISO 14971:2019. Hazard analysis, use-error evaluation, and clinical risk mitigation must actively inform design iterations, not just serve as documentation exercises.Usability Engineering (IEC 62366-1): Integrate human factors engineering throughout the design process. Conduct formative and summative usability testing to ensure the device interface minimizes use-related risks and aligns with the intended user environment.Software Validation & Cybersecurity: For software components, comply with IEC 62304 (Medical Device Software Lifecycle). Implement proactive cybersecurity measures (e.g., FDA Premarket Cybersecurity Guidance, IEC 81001-5-1) to protect against unauthorized access and ensure data integrity.Biocompatibility & Sterilisation Validation: If the device contacts the human body, conduct biological evaluations per ISO 10993. For sterile devices, validate sterilisation processes (e.g., ISO 11135 for EtO, ISO 11137 for radiation) and shelf-life stability.Phase 2: Clinical Investigation & BiostatisticsEthics & Good Clinical Practice (GCP) Infrastructure: Compliance with ICH E6(R3) Good Clinical Practice is non-negotiable. This includes securing Ethics Committee (IRB) approvals before enrollment and ensuring robust Informed Consent processes, particularly regarding data privacy (GDPR/HIPAA) for trial participants.Early Biostatistical Involvement: Involve biostatisticians during protocol development to define endpoints, estimands (per ICH E9(R1)), and sample sizes. This ensures the trial is appropriately powered to detect clinically meaningful effects without exposing patients to unnecessary risk.Protocol & SAP Alignment: Finalise the Statistical Analysis Plan (SAP) and Clinical Investigation Plan (CIP) prior to data collection. Align studies with ISO 14155 (for devices) or ISO 20916 (for IVDs), and strictly adhere to the SAP to prevent data dredging or bias.Randomisation & Blinding: Implement robust, validated randomisation algorithms (e.g., via an Interactive Response Technology system) and appropriate blinding mechanisms to minimise selection and performance bias.Data Quality & Traceability: Adhere to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, Available). For FDA submissions, format data to CDISC standards (SDTM/ADaM) to streamline regulatory review (encouraged by CDRH for devices).Handling Missing Data & Interim Analyses: Pre-specify methods for handling missing data (e.g., multiple imputation) and sensitivity analyses. If interim analyses are planned, strictly control Type I error using predefined alpha-spending functions (e.g., Lan-DeMets).Regulatory Engagement: Utilise pre-submission meetings (e.g., FDA Pre-Subs, MHRA Innovation Meetings) to align on complex statistical methodologies or novel endpoints before initiating the trial.Independent Data Monitoring Committees (IDMCs) and Clinical Event Committees (CECs): An IDMC assesses safety data at interim looks to recommend early stopping for safety or futility. A CEC provides independent, blinded adjudication of complex or subjective clinical endpoints (e.g., stent thrombosis, major adverse cardiac events). Regulators heavily scrutinise endpoint adjudication.Validated Electronic Systems (21 CFR Part 11 / Annex 11): All electronic systems used in the trial, such as Electronic Data Capture (EDC), ePROs, and Interactive Response Technology (IRT) for randomisation, must be fully validated to ensure audit trails, electronic signatures, and data integrity meet FDA and EU standards.Investigator Training & Site Qualification: Sponsors must ensure investigators are adequately trained on the device, the CIP, and the reporting of Adverse Events (AEs) and Serious Adverse Events (SAEs) within strict regulatory timelines (under EU MDR: 2 calendar days for events indicating imminent risk of death or serious injury requiring prompt remedial action, 7 calendar days for other reportable events; 3 calendar days investigator-to-sponsor under ISO 14155).Phase 3: Submission and Post-Market LifecycleComprehensive Submission Packaging: Compile Clinical Study Reports (CSRs) and technical documentation that clearly map clinical data to safety and performance claims. Ensure statistical narratives are defensible and transparent.Post-Market Surveillance (PMS): Compliance does not end at market launch. Under the EU MDR/IVDR, proactively plan Post-Market Clinical Follow-up (PMCF) studies and continuous data analysis to monitor long-term device safety, detect algorithmic drift (particularly for AI/ML devices), and fulfil ongoing regulatory obligations.Continuous Clinical Evaluation (CER): Compile and continuously update the Clinical Evaluation Report per EU MDR Article 61. This document must synthesise clinical investigation data, post-market surveillance, and relevant scientific literature to prove the risk-benefit profile remains acceptable.Supplier Quality Agreements: Establish formal Quality Agreements with all critical suppliers and contract manufacturing organisations (CMOs). Maintain an approved supplier list and conduct routine audits to ensure external partners comply with your QMS.Continuous Training: Maintain a culture of compliance through ongoing training in evolving regulations (e.g., MDR amendments, FDA AI/ML guidance) and statistical best practices across R&D, QA, and clinical teams.Achieving regulatory compliance requires a synthesis of robust engineering, clinical foresight, and statistical rigour. Take advantage of a Free initial consultation with Anatomise Biostats to proactively plan the biometrics and statistical framework for your product development lifecycle.

In the fast-paced world of medical technology, the drive for rapid innovation must be carefully balanced with patient safety. While pushing the boundaries of engineering is essential for advancing healthcare, it must never come at the expense of rigorous safety standards. When regulatory oversight fails to keep pace with technological advancement, or when loopholes allow for lower standards in certain markets, patient safety can be compromised.Fortunately, the medical device industry is highly regulated. As technology evolves and global markets become more interconnected regulatory frameworks must adapt to ensure that all patients are afforded the same level of protection, regardless of where they live.The Jurisdictional Loophole of “Export Only” DevicesThe United States represents over 40% of global medical device revenue, and roughly 10% of Americans currently have a medical device implanted. While these devices generally improve quality of life, they are not without risks. Over the past decade, the FDA has received millions of adverse event reports, including tens of thousands of deaths associated with medical devices.To maintain high domestic safety standards, the FDA requires extensive clinical validation of high risk products before a device can be marketed to US citizens. Despite this an ongoing regulatory gap exists: devices that lack FDA clearance or approval for domestic use can still receive an “Export Only” designation. As of 2018, approximately 4,600 medical devices were registered with the FDA as export-only.This “Export Only” status allows manufacturers to sell these devices internationally. Foreign regulators sometimes approve these devices based on the FDA’s initial involvement, mistaking an FDA facility registration number for actual product clearance.How does this happen? The primary driver is differential device classification. A device deemed high-risk by the FDA might be classified as lower-risk by an importing country’s regulatory body. For example, while implantable devices containing biologics require stringent clinical validation globally, standard implantable devices (such as IIa devices intended for diagnostic or monitoring purposes) may only require a CE mark in Europe or Australia. This lower classification allows a device that failed US clinical scrutiny to enter foreign markets with a significantly reduced burden of evidence. Patients in these importing countries are rarely informed of the device’s domestic regulatory status.Update: Joint replacements have been Class III in the EU since Directive 2005/50/EC took effect in September 2007, and in Australia since July 2012. The MDR maintains this under Rule 8.Regulatory Standards Must Evolve with TechnologyBeyond international trade loopholes, local regulators face a more fundamental challenge: keeping pace with the complexity of modern medical devices.It is no longer enough to rely on static safety standards. Regulators must continuously reassess their frameworks to ensure they are adequate for evaluating novel technologies. As devices become more complex, advanced statistical and computational methods (such as causal inference, agent-based models, and Bayesian methods) are becoming essential tools for calibrating risk and validating device safety.When a device combines hardware with software, particularly artificial intelligence (AI), the need for dynamic regulation increases exponentially. Regulators must now evaluate the reliability of machine learning algorithms, track software degradation over time, assess cybersecurity vulnerabilities, and monitor how AI adapts to real-world stimuli; all alongside the physical safety of the device itself.Lessons from Recent Medical Device LitigationRecent class-action lawsuits highlight the consequences of inadequate validation and testing across the industry.Johnson & Johnson: J&J has faced significant litigation regarding its vaginal mesh products and electrosurgical devices. In the mesh cases, thousands of adverse events were reported to the FDA, including serious injuries and a loss of quality of life for patients. Similarly, lawsuits regarding surgical tools alleged that the devices caused burn injuries to patients. These cases underscore the critical need for comprehensive pre-market testing, both in clinical trials and post-market surveillance, to ensure long-term safety.Pulse Oximeters and Racial Bias: Recent legal action against Apple regarding its blood oxygen sensor highlighted a systemic issue in pulse oximetry technology. This has posed a problem for certain users who may rely on the data for health status. Darker skin has been found to absorb more light at certain wavelengths, these sensors can provide falsely elevated blood oxygen readings for people with darker skin tones. This limitation, which spans across multiple manufacturers, potentially contributed to adverse health outcomes during the pandemic. The Apple Watch feature was marketed as a wellness tool rather than an FDA-cleared medical device, it thereby bypassed the clinical validation required for medical-grade pulse oximeters. This issue could have been better mitigated if it was subject to a clinical investigation and that study had recruited a broad spectrum of participants, stratified by skin tone, and if those limitations had been transparently reported on product labeling.Strengthening Global Regulatory OversightTo maintain trust in medical technology, regulatory bodies worldwide must take proactive steps to close existing loopholes and prepare for future complexities.Flagging “Export Only” Devices: Any device given “Export Only” status by the FDA, or its equivalent by another regulatory body, should be automatically flagged by importing national regulators as requiring additional scrutiny. Local agencies should demand the specific clinical data that led to the device failing domestic approval in its country of origin.Harmonising Risk Classifications: Global regulatory bodies must work toward harmonising device classifications. An implantable device deemed high-risk in one developed nation should not bypass clinical scrutiny simply by crossing a border.Dynamic Post-Market Surveillance: As AI and software-driven devices become the norm, regulators must require continuous post-market surveillance. Real-world data collection must be standard practice to ensure algorithms do not drift or develop biases over time.Putting Patients FirstThe ultimate goal of medical device development is to improve health outcomes, alleviate suffering, and save lives. A culture of responsible innovation requires developers to prioritize patient safety over short-term financial gains.While collecting international data on “Export Only” devices can be an attractive way for companies to generate revenue and gather real-world evidence for future FDA applications, it cannot be done at the expense of uninformed patients. National regulatory agencies must maintain strict classification and clinical evidence standards to ensure their citizens are not exposed to undue, undisclosed risks.Collaboration and TransparencyThe medical device industry must embrace a culture of transparency. Open dialogue among developers, regulators, healthcare professionals, and patients ensures a holistic approach to device development. Sharing data regarding device failures, adverse events, and software vulnerabilities can help prevent the repetition of past mistakes across the industry.By prioritising patient well-being, adopting transparent practices, and modernising regulatory frameworks to match the pace of innovation, the medical technology sector can continue to advance safely and ethically.Effective Strategies for Regulatory ComplianceFor medical device developers navigating this complex landscape, the following strategies are essential:Establish a Regulatory Compliance Plan: Develop a comprehensive plan that outlines regulatory requirements and compliance strategies for each stage of the product development process.Engage with Regulatory Authorities Early: Build relationships with regulatory authorities and engage with them early to ensure all requirements are met and potential roadblocks are identified.Conduct Comprehensive Risk Assessments: Identify potential risks and hazards associated with the product, including software and algorithmic biases, and develop robust risk management strategies.Implement Quality Management Systems: Establish quality management systems that ensure compliance with regulatory requirements and promote continuous improvement.Document Everything: Maintain detailed records of all activities related to the product development process, including design, testing, and manufacturing, to demonstrate compliance.Further Reading & SourcesDrugs and Devices: Comparison of European and U.S. Approval Processes – ScienceDirectAddressing the Medical Device Safety Crisis – The Regulatory ReviewMedtech Regulation: FDA and EU MDR Outlook – MedTech DiveGlobal Medical Devices Market Forecast – Market Data ForecastFDA Permits ‘Export Only’ Medical Devices – Industrial Equipment NewsFDA Issues ‘Most Serious’ Recall Over Johnson & Johnson Surgical ToolsJury Award in Vaginal Mesh Lawsuit Could Open Flood Gates – MDDI OnlineLawsuit Alleges Apple Watch’s Blood Oxygen Sensor ‘Racially Biased’ – ABC News / Inferse

Stata has been widely used for decades in various research domains such as economics, biosciences, health and social sciences, including clinical trials. It is widely referenced in studies published in reputable scientific journals. While SAS has a longer history of being explicitly referenced by regulatory agencies such as the FDA, Stata can still meet regulatory compliance requirements in clinical trials. StataCorp actively engages with researchers, regulatory agencies, and industry professionals to address compliance needs and provide technical support, thereby maintaining a strong commitment to producing high-quality software and staying up to date with industry standards.Stata’s commitment to accuracy, comprehensive documentation, integrated versioning, and rigorous certification processes provides researchers with a reliable and compliant statistical software for regulatory submissions. Stata’s worldwide reputation, excellent technical support, verification of data integrity, and ease of obtaining updates further contribute to its suitability for clinical trials and regulatory compliance.To facilitate regulatory compliance in clinical trials, Stata offers features such as data documentation and audit trails, allowing researchers to document and track data manipulation steps for reproducibility and transparency. Stata’s built-in “do-files” and “log-files” can capture commands and results, aiding in the audit trail process. Stata provides the flexibility to generate analysis outputs and tables in formats commonly required for regulatory reporting (e.g., PDF, Excel, or CSV). It also enables the automation of reproducible, fully-formatted publication standard reports. Strong TLF and CRF programming used to be the domain of SAS which explains their early industry dominance. SAS was developed in 1966 using funding from the National Institutes of Health. In recent years, however, Stata has arguably surpassed what is achievable in SAS with the same efficiency, particularly in the context of clinical trials.Stata has extensive documentation of adaptive clinical trial design. Adaptive group sequential designs can be achieved using the GSD functionality. The default graphs and tables produced using GSD analysis really do leave SAS in the dust being more visually appealing and easily interpretable. They are also more highly customisable than what can be produced in SAS. Furthermore the Stata syntax used to produce them is minimal compared to corresponding SAS commands, while still retaining full reproducibility.Stata’s comprehensive causal inference suite enables experimental-style causal effects to be derived from observational data. This can be helpful in planning clinical trials based on observed patient data that is already available, with the process being fully documentable.Advanced data science methods are being increasingly used in clinical trial design and planning as well as for follow-up exploratory analysis of clinical trial data. Stata has both supervised and unsupervised machine learning capability in its own right for decades. Stata can also integrate with other tools and programming languages, such as Python via PyStata and PyTrials, if additional functionalities or specific formats are needed. This can be instrumental for advanced machine learning and other data science methods goes beyond native features and user-made packages in terms of customisability. Furthermore, using Python within the Stata interface allows for compliant documentation of all analyses. Python integration is also available in SAS via numerous packages and is able to eliminate some of the limitations of native SAS, particularly when it comes to graphical outputs.Stata for FDA regulatory complianceWhile the FDA does not mandate the use of any specific statistical software, they emphasise the need for reliable software with appropriate documentation of testing procedures. Stata satisfies the requirements of the FDA and is recognised as one of the most respected and validated statistical tools for analysing clinical trial data across all phases, from pre-clinical to phase IV trials. With Stata’s extensive suite of statistical methods, data management capabilities, and graphics tools, researchers can rely on accurate and reproducible results at every step of the analysis process.When it comes to FDA guidelines on statistical software, Stata offers features that assist in compliance. Stata provides an intuitive Installation Qualification tool that generates a report suitable for submission to regulatory agencies like the FDA. This report verifies that Stata has been installed properly, ensuring that the software meets the necessary standards.Stata offers several key advantages when it comes to FDA regulatory compliance for clinical trials. Stata takes reproducibility seriously and is the only statistical package with integrated versioning. This means that if you wrote a script to perform an analysis in 1985, that same script will still run and produce the same results today. Stata ensures the integrity and consistency of results over time, providing reassurance when submitting applications that rely on data and results from clinical trials.Stata also offers comprehensive manuals that detail the syntax, use, formulas, references, and examples for all commands in the software. These manuals provide researchers with extensive documentation, aiding in the verification and validity of data and analyses required by the FDA and other regulatory agencies.To further ensure computational validity, Stata undergoes extensive software certification testing. Millions of lines of certification code are run on all supported platforms (Windows, Mac, Linux) with each release and update. Any discrepancies or changes in results, output, behaviour, or performance are thoroughly reviewed by statisticians and software engineers before making the updated software available to users. Stata’s accuracy is also verified through the National Institute of Standards and Technology (NIST) StRD numerical accuracy tests and the George Marsaglia Diehard random-number generator tests.Data management in StataStata’s Datasignature commands and other similar features offer powerful tools for data validation, quality control, and documentation. These features enable users to thoroughly examine and understand their datasets, ensuring data integrity and facilitating transparent research practices.1. Datasignature commands:Stata’s datasignature commands are a collection of commands in Stata that assists in data validation and documentation. It includes commands such as datasignature, which computes a checksum of the data and reports changes to variable counts, names, order and storage types. These commands help identify unintended changes and potential errors in the data.2. Variable labelling: Stata allows users to assign meaningful labels to variables, enhancing data documentation and interpretation. With the `label variable` command, users can provide descriptive labels to variables, making it easier to understand their purpose and content. This feature improves collaboration among researchers and ensures that the dataset remains comprehensible even when shared with others.3. Value labels: In addition to variable labels, Stata supports value labels. Researchers can assign descriptive labels to specific values within a variable, transforming cryptic codes into meaningful categories. Value labels enhance data interpretation and eliminate the need for constant reference to codebooks or data dictionaries.4. Data documentation:Stata encourages comprehensive data documentation through features like variable and dataset-level documentation. Users can attach detailed notes and explanations to variables, datasets, or even individual observations, providing context and aiding in data exploration and analysis. Proper documentation ensures transparency, reproducibility, and facilitates data sharing within research teams or with other stakeholders.5. Data transformation:Stata provides a wide range of data transformation capabilities, enabling users to manipulate variables, create new variables, and reshape datasets. These transformations facilitate data cleaning, preparation, and restructuring, ensuring data compatibility with statistical analyses and modelling procedures.6. Data merging and appending:Stata allows users to combine multiple datasets through merging and appending operations. By matching observations based on common identifiers, researchers can consolidate data from different sources or time periods, facilitating longitudinal or cross-sectional analyses. This feature is particularly useful when dealing with complex study designs or when merging administrative or survey datasets.7. Data export and import:Stata integrates various file formats, allowing users to import data from external sources or export datasets for further analysis or sharing. Supported formats include Excel, CSV, SPSS, SAS, and more. This versatility enhances data interoperability and enables collaboration with researchers using different software.These features collectively contribute to data management best practices, ensuring data quality, reproducibility, and documentation. By leveraging the Datasignature Suite and other data management capabilities in Stata, researchers can confidently analyse their data and produce reliable results while maintaining transparency and facilitating collaboration within the scientific community.Stata and maintaining CDISC standards. How does it compare to SAS?Stata and SAS are both statistical software packages commonly used in the fields of data analysis, including in the pharmaceutical and clinical research industries. While they share some similarities, there are notable differences between the two when it comes to working with CDISC standards:CDISC Support:SAS has extensive built-in support for CDISC standards. SAS provides specific modules and tools, such as SAS Clinical Standards Toolkit, which offer comprehensive functionalities for CDASH, SDTM, and ADaM. These modules provide pre-defined templates, libraries, and validation rules, making it easier to implement CDISC standards directly within the SAS environment. Stata, on the other hand, does not have native, dedicated modules specifically designed for CDISC standards. However, Stata’s flexibility allows users to implement CDISC guidelines through custom programming and data manipulation.2. Data Transformation:SAS has robust built-in capabilities for transforming data into SDTM and ADaM formats. SAS provides specific procedures and functions tailored for SDTM and ADaM mappings, making it relatively straightforward to convert datasets into CDISC-compliant formats. Stata, while lacking specific CDISC-oriented features, offers powerful data manipulation functions that allow users to reshape, merge, and transform datasets. Stata users may need to develop custom programming code to achieve CDISC transformations.3. Industry Adoption:SAS has been widely adopted in the pharmaceutical industry and is often the preferred choice for CDISC-compliant data management and analysis. Many pharmaceutical companies, regulatory agencies, and clinical research organisations have established workflows and processes built around SAS for CDISC standards. Stata, although less commonly associated with CDISC implementation, is still a popular choice for statistical analysis across various fields, including healthcare and social sciences. Stata has the potential to make adherence to CDISC standards a more affordable option for small companies and therefore an increased priority.4. Learning Curve and Community Support:SAS has a long been the default preference in the context of CDISC compliance and is what statistical programmers are used to, thus SAS is known for its comprehensive documentation and extensive user community. Resources including training materials, user forums, and user groups, which can facilitate learning and support for CDISC-related tasks. Stata also has an active user community and provides detailed documentation, but its community may be comparatively smaller in the context of CDISC-specific workflows. Stata, as a more efficient language, has the potential to reduce the volume of programming required to achieve CDISC compliance, for example in the creation of SDTM and ADaM data sets.While SAS offers dedicated modules and tools specifically designed for CDISC standards, Stata provides flexibility and powerful data manipulation capabilities that can be leveraged to implement CDISC guidelines. The choice between SAS and Stata for CDISC-related work may depend on factors such as industry norms, organisational preferences, existing infrastructure, and individual familiarity with the software.SAS has historically been more explicitly associated with regulatory compliance in the clinical trial domain, Stata is however fully equipped to fulfil regulatory requirements and has long been used effectively in clinical research. Researchers often choose the software they are most comfortable with and consider factors such as data analysis capabilities, familiarity, and support when deciding between SAS and Stata for their regulatory compliance needs.It is important to note that compliance requirements can vary based on specific regulations and guidelines. Researchers are responsible for ensuring their analysis and reporting processes align with the appropriate regulatory standards and should consult relevant regulatory authorities when necessary.New in Stata 19: Advanced Analytics for Modern Clinical Trials (Update)With the release of Stata 19, biostatisticians gain a comprehensive suite of tools tailored to the increasingly complex demands of modern medical device and drug development. A major focus of this update is the expansion of causal inference capabilities, which are essential for analysing real-world data (RWD) and observational studies that increasingly support regulatory submissions. Stata 19 introduces commands for conditional average treatment effects (CATE) to explore treatment heterogeneity across patient subgroups, alongside local average treatment effects (LATE), causal mediation with two mediators, and control-function models. For trials facing non-compliance or endogeneity, Stata now offers inference robust to weak instruments, instrumental-variables local-projection IRFs, and SVAR models via instrumental variables, ensuring that causal estimates submitted to regulators are statistically defensible.Survival analysis and longitudinal modeling, cornerstones of clinical trial endpoints, have also seen significant upgrades. Stata 19 adds the interval-censored multiple-event Cox model, allowing biostatisticians to analyse complex time-to-event data (such as the onset of multiple adverse events) when exact event times are unknown. For panel data and repeated measures, new high-dimensional fixed effects (HDFE) allow researchers to absorb multiple categorical covariates with remarkable speed gains, while the new panel-data vector autoregressive (VAR) model, correlated random-effects (CRE) model, and Mundlak specification test provide deeper insights into patient trajectories over time. Furthermore, literature synthesis for Clinical Evaluation Reports (CERs) under EU MDR/IVDR is enhanced through meta-analysis for correlations.To address the FDA’s growing acceptance of Bayesian methods and machine learning in regulatory science, Stata 19 integrates directly with H2O for ensemble decision trees (random forests and gradient boosting machines), enabling advanced predictive modeling and subgroup discovery directly within the Stata environment. Bayesian analysis is vastly expanded with Bayesian variable selection for linear models, Bayesian quantile regression, the Bayesian asymmetric Laplace model for simultaneous and multilevel quantile regression, and the Bayesian bootstrap for robust inference in small sample sizes. Rounding out the statistical suite are additions like latent class model-comparison statistics, proportional odds tests, and power analysis for logistic regression.Finally, Stata 19 introduces critical workflow enhancements that directly support ALCOA+ data integrity principles and audit-readiness. The generation of submission-ready Tables, Listings, and Figures (TLFs) is streamlined with new graphics (including bar graphs with confidence intervals and heat maps) and a unified table creation system that allows for easier tabulations and exporting. Reproducibility and traceability are non-negotiable in regulatory compliance. These are bolstered by Do-file Editor enhancements (autocompletion, templates, and code folding), the ability to modify multiple datasets (frames) without loading them into memory, and seamless import of Parquet data. These updates, alongside continuous StataNow™ features, ensure that clinical trial data management, analysis, and reporting remain transparent, fully documented, and audit-ready for regulatory authorities.